DRMA
Dermata Therapeutics, Inc.NASDAQHealthcare$1.32+2.33%ClosedMarket Cap: $899,655
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.26
P/S
0.00
EV/EBITDA
0.87
DCF Value
$8,120.93
FCF Yield
-862.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-130.9%
ROA
-96.1%
ROIC
-124.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-1.9M | $-1.9M | $-1.52 | — |
| FY 2025 | $0.00 | NaN% | $-7.8M | $-7.6M | $-8.16 | — |
| Q3 2025 | $0.00 | NaN% | $-1.8M | $-1.7M | $-1.65 | — |
| Q2 2025 | $0.00 | NaN% | $-1.8M | $-1.7M | $-1.66 | — |
| Q1 2025 | $0.00 | NaN% | $-2.3M | $-2.3M | $-4.47 | — |
| Q4 2024 | $0.00 | NaN% | $-3.2M | $-3.2M | $-20.40 | — |
| FY 2024 | $0.00 | NaN% | $-12.5M | $-12.3M | $-80.32 | — |
| Q3 2024 | $0.00 | NaN% | $-3.2M | $-3.2M | $-20.40 | — |
| Q2 2024 | $0.00 | NaN% | $-2.9M | $-2.8M | $-41.82 | — |
| Q1 2024 | $0.00 | NaN% | $-3.2M | $-3.1M | $-70.58 | — |
| Q4 2023 | $0.00 | NaN% | $-2.2M | $-2.1M | $-5.40 | — |
| FY 2023 | $0.00 | NaN% | $-8.0M | $-7.8M | $-399.81 | — |